Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $4.0300 (7.9%) ($3.6750 - $4.0300) on Fri. Jun. 17, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.98% (three month average) | RSI | 41 | Latest Price | $4.0300(7.9%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.7% a day on average for past five trading days. | Weekly Trend | TGTX declines -5.7% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(74%) ARKG(70%) ARKK(65%) IBB(64%) IBUY(58%) | Factors Impacting TGTX price | TGTX will decline at least -3.49% in a week (0% probabilities). VXX(-65%) VIXM(-53%) TBT(-23%) UUP(-18%) USO(-14%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.49% (StdDev 6.98%) | Hourly BBV | 0.9 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-18.67(-563.28%) | Resistance Level | $4.47 | 5 Day Moving Average | $3.92(2.81%) | 10 Day Moving Average | $4.21(-4.28%) | 20 Day Moving Average | $4.47(-9.84%) | To recent high | -61.8% | To recent low | 7.9% | Market Cap | $510m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |